For Patients: Clinical Trials
Publications
Careers
Contact Us
Toggle navigation
About INOVIO
Purpose, Mission and Values
Leadership
Partnerships
DNA Medicines Technology
Optimized Plasmid Design and Delivery
DNA Medicines Explained
The Promise of DNA Medicine
NEXT GEN DNA MEDICINE
DNA Medicines Pipeline
Investors & Media
Events & Presentations
Stock Information
News Releases
SEC Filings
Analyst Coverage
Corporate Governance
Shareholder Services
FAQ
For Patients: Clinical Trials
Publications
Careers
Contact Us
About INOVIO
DNA Medicines Technology
Optimized Plasmid Design and Delivery
DNA Medicines Explained
Technology Advantages
NEXT GENERATION DNA MEDICINE
DNA Medicines Pipeline
Investors & Media
Events & Presentations
Stock Information
News Releases
SEC Filings
Analyst Coverage
Corporate Governance
Shareholder Services
FAQ
For Patients: Clinical Trials
Publications
Careers
Contact Us
Purpose, Mission and Values
Leadership
Partnerships
CEO CORNER
Dr. J. Joseph Kim
J. Joseph Kim, Ph.D.
President, Chief Executive Officer, Director
CEO CORNER
Dr. J. Joseph Kim
J. Joseph Kim, Ph.D.
President, Chief Executive Officer, Director
xxx
Synthetic DNA-Encoded Monoclonal Antibody Delivery of Anti–CTLA-4 Antibodies Induces Tumor Shrinkage In Vivo
© Copyright 2024 INOVIO Pharmaceuticals. All rights reserved.
